How do I find recruiting Non-small Cell Lung Cancer clinical trials?

Browse the actively recruiting Non-small Cell Lung Cancer studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.

Are Non-small Cell Lung Cancer clinical trials free to join?

Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.

Who can take part in a Non-small Cell Lung Cancer clinical trial?

Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.

Non-small Cell Lung Cancer Clinical Trials

Non-small Cell Lung Cancer clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for non-small Cell Lung Cancer. Corterve aggregates actively recruiting Non-small Cell Lung Cancer studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.

Browse all Non-small Cell Lung Cancer trials Take the assessment

Recruiting Non-small Cell Lung Cancer studies

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215PHASE3Hoffmann-La RocheNon-Small Cell Lung CancerAnchorage, Alaska
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790PHASE3Bristol-Myers SquibbNon-Small Cell Lung CancerBeverly Hills, California
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298PHASE1, PHASE2PfizerAdvanced/Metastatic Non-Small Cell Lung CancerFayetteville, Arkansas
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782PHASE2Verastem, Inc.Non-Small Cell Lung CancerLos Angeles, California
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
NCT07566052PHASE3Astellas Pharma Global Development, Inc.Non-small Cell Lung Cancer (NSCLC)Glendale, California
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
NCT06731907PHASE2Merck Sharp & Dohme LLCNon-small Cell Lung CancerLexington, Kentucky
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695PHASE3Boehringer IngelheimNon-small Cell Lung CancerFresno, California
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07115043PHASE1, PHASE2AstraZenecaMelanomaGrand Rapids, Michigan
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT05579366PHASE1, PHASE2GenmabHigh Grade Epithelial Ovarian CancerPhoenix, Arizona
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566PHASE3PfizerAdvanced Non-Small Cell Lung CancerBullhead City, Arizona
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
NCT07190248PHASE3Merck Sharp & Dohme LLCNon-small Cell Lung CancerBirmingham, Alabama
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729PHASE3Merck Sharp & Dohme LLCNon-small Cell Lung CancerBakersfield, California

See all 227 recruiting trials →

Non-small Cell Lung Cancer trials by state

Non-small Cell Lung Cancer trials by metro

Frequently asked questions

How do I find recruiting Non-small Cell Lung Cancer clinical trials?: Browse the actively recruiting Non-small Cell Lung Cancer studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
Are Non-small Cell Lung Cancer clinical trials free to join?: Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
Who can take part in a Non-small Cell Lung Cancer clinical trial?: Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.